TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17056939

Group type: EXPERIMENTAL
Intervention: 12.5% carbohydrate drink (CHO)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Flavored water (placebo)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Fasting overnight (control)
Number of subjects: 188
Study: 12609561

Group type: EXPERIMENTAL
Intervention: CR BNO 1055 (daily dose corresponding to 40 mg herbal drug)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.6 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CR BNO 1055
Number of subjects: 62
Study: 10636491

Group type: EXPERIMENTAL
Intervention: lamivudine plus zidovudine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: lamivudine plus stavudine
Number of subjects: 16

Group type: COMPARATOR
Intervention: lamivudine plus zidovudine or stavudine
Number of subjects: 16
Study: 8873431

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 7911271

Group type: EXPERIMENTAL
Intervention: Immediate-release nisoldipine (20 mg twice daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 2821477

Group type: EXPERIMENTAL
Intervention: Experimental rotavirus vaccine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (40 children)
Number of subjects: 50
Study: 29436142

Group type: EXPERIMENTAL
Intervention: AXOS (9.4 g)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (10 g maltodextrin + 1 g unlabelled lactose ureide)
Number of subjects: 13
Study: 24621126

Group type: EXPERIMENTAL
Intervention: Active charcoal filter
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard particle filter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unfiltered DE
Number of subjects: 30

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diesel exhaust PM
Number of subjects: 30
Study: 22807538

Group type: EXPERIMENTAL
Intervention: MATI protocol
Number of subjects: 225

Group type: COMPARATOR
Intervention: Conventional (non-MATI) clinical follow-up
Number of subjects: 225
Study: 20430253

Group type: EXPERIMENTAL
Intervention: H. pylori eradication plus ferrous sulfate supplementation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ferrous sulfate supplementation (noninfected children)
Number of subjects: 72
Study: 18712409

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition supplemented with alanyl-glutamine dipeptide (Gln)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Regular parenteral nutrition (Control)
Number of subjects: 70
Study: 15759218

Group type: EXPERIMENTAL
Intervention: Mental practice (MP) protocol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Relaxation techniques (Control)
Number of subjects: 11
Study: 12660668

Group type: EXPERIMENTAL
Intervention: Method 1: Hospital charges
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: Method 2: Hospital charges converted to costs using hospital-level cost-to-charge ratios
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: Method 3: Hospital charges converted to costs using department-level cost-to-charge ratios
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: Method 4: Itemized catheterization laboratory costs with nonprocedural hospital costs from department-level cost-to-charge ratios
Number of subjects: 1849
Study: 10555930

Group type: EXPERIMENTAL
Intervention: MK‐571
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7675582

Group type: EXPERIMENTAL
Intervention: Breathing retraining procedure
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no breathing process)
Number of subjects: 46
Study: 1980542

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment under open conditions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment under double-blind conditions
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo under double-blind conditions
Number of subjects: 17
Study: 7448103

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.015 mg kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.02 mg kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gallamine 0.3 mg kg‐1
Number of subjects: 80
Study: 31657021

Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) program
Number of subjects: 381

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 381
Study: 31510871

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Combination of dexmedetomidine 0.5 μg/kg and dexamethasone 5 mg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 149
Study: 28371868

Group type: EXPERIMENTAL
Intervention: Press tack needles
Number of subjects: 60

Group type: COMPARATOR
Intervention: Press tack placebos
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conservative therapy including classical needle acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conservative therapy without classical needle acupuncture
Number of subjects: 60
Study: 26178727

Group type: COMPARATOR
Intervention: Biofortified maize intervention
Number of subjects: 140
Study: 23696281

Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 86
Study: 20694473

Group type: EXPERIMENTAL
Intervention: PureVision (Balafilcon A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Biofinity (Comfilcon A)
Number of subjects: 20
Study: 19037756

Group type: EXPERIMENTAL
Intervention: 17 mg Polaprezinc daily for 12 weeks
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 34 mg Polaprezinc daily for 12 weeks
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 68 mg Polaprezinc daily for 12 weeks
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 17097523

Group type: EXPERIMENTAL
Intervention: Patient activation intervention (mailing DXA scan results + call from nurse educator)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study: 15251273

Group type: EXPERIMENTAL
Intervention: 5 mg/16 h nicotine patches (Nicorette)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11371413

Group type: EXPERIMENTAL
Intervention: O(3) > 80 ppb
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NQO1wt and GSTM1null subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Other haplotypes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: O(3) exposure
Number of subjects: 24
Study: 9209767

Group type: EXPERIMENTAL
Intervention: Migraine group
Number of subjects: 73
Study: 7936730

Group type: EXPERIMENTAL
Intervention: Analgesic upon onset of sensation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Analgesic upon onset of pain
Number of subjects: 0
Study: 2975448

Group type: EXPERIMENTAL
Intervention: 2.5, 5, 10, or 20 micrograms dose of recombinant yeast-derived hepatitis B vaccine
Number of subjects: 220

Group type: COMPARATOR
Intervention: 20 micrograms dose of plasma-derived vaccine
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 20 micrograms booster dose of recombinant vaccine
Number of subjects: 220
Study: 31838010

Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg once daily for 3 weeks on, 1 week off) plus daily letrozole (2·5 mg/day) for 24 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Chemotherapy (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days followed by weekly paclitaxel 80 mg/m2 for 12 weeks) for 24 weeks
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 106

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 106
Study: 29674370

Group type: EXPERIMENTAL
Intervention: 2 g dose of cephalexin administered 40‐60 min prior to surgery
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 28339576

Group type: EXPERIMENTAL
Intervention: Post-treatment e-cigarette users
Number of subjects: 217

Group type: COMPARATOR
Intervention: Nonusers
Number of subjects: 217
Study: 25261492

Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 2299

Group type: COMPARATOR
Intervention: Control (uncircumcised)
Number of subjects: 2299
Study: 22958160

Group type: COMPARATOR
Intervention: Phacoemulsification (Phaco)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combined phacoemulsification and viscogonioplasty (Phaco‐VGP)
Number of subjects: 67
Study: 20375805

Group type: EXPERIMENTAL
Intervention: HPV‐16/18 AS04‐adjuvanted vaccine
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Hepatitis A vaccine (Control)
Number of subjects: 1040
Study: 18339475

Group type: EXPERIMENTAL
Intervention: Continuous androgen suppression (CAS)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Systematically interrupted androgen suppression (SIAS)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Both CAS and SIAS
Number of subjects: 129
Study: 16988140

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation intervention (home visits and group meetings for 12 months)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (undernourished children without psychosocial stimulation)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Intervened children (psychosocial stimulation)
Number of subjects: 107
Study: 14753593

Group type: EXPERIMENTAL
Intervention: Monophasic injection protocol (123 mL at 2.5 mL/s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Biphasic injection protocol (123 mL, 60 mL at 1.5 mL/s and then 63 mL at 2.5 mL/s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sigmoid injection protocol (0.6 mL/s ending at 2.5 mL/s)
Number of subjects: 60
Study: 10793867

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 23
Study: 8632222

Group type: EXPERIMENTAL
Intervention: Low fiber diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coarse whole meal rye bread diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fine whole meal rye bread diet
Number of subjects: 0
Study: 1600772

Group type: EXPERIMENTAL
Intervention: Greatest response-invoking agent (specific agent not mentioned)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Least response-invoking agent (specific agent not mentioned)
Number of subjects: 18
Study: 6383836

Group type: EXPERIMENTAL
Intervention: mexiletine
Number of subjects: 99

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 99
Study: 30952581

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Active control tVNS
Number of subjects: 76
Study: 30204239

Group type: EXPERIMENTAL
Intervention: Elotuzumab plus lenalidomide and dexamethasone (ELd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Ld)
Number of subjects: 0
Study: 26310842

Group type: EXPERIMENTAL
Intervention: 10-item German short version of the Örebro Musculoskeletal Pain Questionnaire (ÖMSPQ)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: ÖMSPQ subscales on pain related disability, depression, and fear-avoidance beliefs
Number of subjects: 360
Study: 25253665

Group type: EXPERIMENTAL
Intervention: LIPO-5 (250 μg)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1452) alone
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1452) + LIPO-5 (250, 750, and 2,500 μg)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1452) + LIPO-5
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 174
Study: 22503302

Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin E on alternate days
Number of subjects: 14236

Group type: EXPERIMENTAL
Intervention: 500 mg of vitamin C daily
Number of subjects: 14236

Group type: COMPARATOR
Intervention: Placebo for vitamin E
Number of subjects: 14236

Group type: COMPARATOR
Intervention: Placebo for vitamin C
Number of subjects: 14236
Study: 20303119

Group type: EXPERIMENTAL
Intervention: 5 mg solifenacin once daily
Number of subjects: 132

Group type: COMPARATOR
Intervention: 5 mg oxybutynin immediate release 3 times daily
Number of subjects: 132
Study: 17414988

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI)
Number of subjects: 84
Study: 15726875

Group type: EXPERIMENTAL
Intervention: Benfotiamine (50 mg tablets, four times daily for three weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Benfotiamine
Number of subjects: 40
Study: 12193488

Group type: EXPERIMENTAL
Intervention: Ilioinguinal-iliohypogastric nerve block with bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline infiltration)
Number of subjects: 0
Study: 9660258

Group type: EXPERIMENTAL
Intervention: Gram-negative intestinal colonization
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gram-negative colonization of the rectum
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gram-negative colonization of the oropharynx
Number of subjects: 90
Study: 7906327

Group type: EXPERIMENTAL
Intervention: Warm heart surgery (37 degrees C cardioplegia with systemic normothermia)
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Cold heart surgery (hypothermic surgery)
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Warm heart surgery
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Cold heart surgery
Number of subjects: 1732
Study: 2567670

Group type: EXPERIMENTAL
Intervention: Metoprolol (M, 100 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pindolol (P, 10 mg)
Number of subjects: 30
Study: 30229693

Group type: EXPERIMENTAL
Intervention: Predialysis cohort
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dialysis cohort
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Transplant wait-list cohort
Number of subjects: 3
Study: 28202699

Group type: EXPERIMENTAL
Intervention: Single infarction with ICAS
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: Single infarction without ICAS
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: Multiple infarctions with ICAS
Number of subjects: 1089

Group type: COMPARATOR
Intervention: No infarction or ICAS
Number of subjects: 1089
Study: 25155428

Group type: EXPERIMENTAL
Intervention: Strontium-89 (Sr-89)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control arm (ADT, doxorubicin, and zoledronic acid)
Number of subjects: 79
Study: 23246919

Group type: EXPERIMENTAL
Intervention: Longer reproductive period (time between menarche and menopause)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Previous hormone therapy (HT) use
Number of subjects: 126
Study: 21955700

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-ASV treatment (control group)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ASV therapy
Number of subjects: 59
Study: 19212427

Group type: EXPERIMENTAL
Intervention: VEGF-adenoviral
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: VEGF-plasmid/liposome
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 16087353

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Waiting-list control group (WG)
Number of subjects: 28
Study: 14567905

Group type: EXPERIMENTAL
Intervention: Patient-centred approach to care with guidebooks on ulcerative colitis and Crohn's disease, including a written self-management plan and self-referral to services.
Number of subjects: 700
Study: 9121225

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 75
Study: 1527231

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2882773

Group type: EXPERIMENTAL
Intervention: temelastine 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 31714393

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (CR) plus usual care
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 142
Study: 31974881

Group type: EXPERIMENTAL
Intervention: Magnetically Controlled Growing Rods (MCGRs) with a lengthening interval of 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Magnetically Controlled Growing Rods (MCGRs) with a lengthening interval of 16 weeks
Number of subjects: 0
Study: 26712942

Group type: EXPERIMENTAL
Intervention: Topical DFMO applied twice daily
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Topical diclofenac applied daily
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: DFMO plus diclofenac
Number of subjects: 156
Study: 24823430

Group type: EXPERIMENTAL
Intervention: Cognitive group therapy combined with pharmacotherapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Happiness training combined with pharmacotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pharmacotherapy only
Number of subjects: 36
Study: 23177226

Group type: EXPERIMENTAL
Intervention: Exercise with incorporated expiratory manoeuvres
Number of subjects: 34

Group type: COMPARATOR
Intervention: Breathing techniques
Number of subjects: 34
Study: 20508081

Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS) 0.6 U/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine 0.6 U/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 17880992

Group type: EXPERIMENTAL
Intervention: Choice between a desirable object and an undesirable object
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choice between a desirable object and an empty location
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent trials with the second object removed and the empty location reintroduced
Number of subjects: 0
Study: 15802149

Group type: COMPARATOR
Intervention: Home cancer healthcare program
Number of subjects: 67

Group type: COMPARATOR
Intervention: Home cancer healthcare program (palliative care)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Home cancer healthcare program (chemotherapy)
Number of subjects: 67
Study: 12242586

Group type: COMPARATOR
Intervention: Standard term formula (SF)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Enriched formula (PDF)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both SF and PDF
Number of subjects: 33
Study: 9952143

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 36

Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 36
Study: 7551935

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 44
Study: 2252966

Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Day treatment
Number of subjects: 24
Study: 7358211

Group type: EXPERIMENTAL
Intervention: Piracetam (4.8 g per day for 4 days and 7.2 g on the 5th day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31668556

Group type: EXPERIMENTAL
Intervention: Wet cupping therapy (WCT) applied once a month for 12 months (Group 2)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (Group 1) received three sessions of WCT
Number of subjects: 109
Study: 31237322

Group type: EXPERIMENTAL
Intervention: High-dairy diet (HDD) (6 or 5 reduced-fat dairy portions for men and women, respectively)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low-dairy diet (LDD) (≤1 dairy portion per day)
Number of subjects: 52
Study: 29065491

Group type: COMPARATOR
Intervention: Enhanced Standard Preparedness
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Community Resilience approach
Number of subjects: 16
Study: 25557762

Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin (rATG)
Number of subjects: 200

Group type: COMPARATOR
Intervention: interleukin 2 receptor antagonists (IL‐2RA)
Number of subjects: 200
Study: 23987161

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 50
Study: 22080012

Group type: EXPERIMENTAL
Intervention: LPS stress (normal vaccination+LPS)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: CPM stress (normal vaccination+CPM)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Normal vaccination (simplified vaccination + second dose of ND‐IB, H120, and AI)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Simplified vaccination (H120, AI, NDV, ND‐IB)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: No vaccination
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 540
Study: 18363763

Group type: EXPERIMENTAL
Intervention: Coping with itch nursing programme
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study: 16434755

Group type: EXPERIMENTAL
Intervention: Phosphate salts (PO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Polyethylene glycol (PG)
Number of subjects: 40
Study: 16807618

Group type: EXPERIMENTAL
Intervention: Eprosartan 600 mg tablet once daily for 10 weeks
Number of subjects: 195
Study: 11050522

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 164

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 164
Study: 10096415

Group type: EXPERIMENTAL
Intervention: Verbal span tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visuospatial span tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 8262292

Group type: EXPERIMENTAL
Intervention: Amox‐CA (Augmentin) 1.2 g intravenous injection, 1 hour after delivery
Number of subjects: 1291

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 1291
Study: 3513943

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Doxorubicin (CA)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Doxorubicin and Cisplatin (CAP)
Number of subjects: 440